Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGTCNASDAQ:CCCCNASDAQ:HLVXNASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/ACCCCC4 Therapeutics$1.68+3.7%$1.44$1.09▼$7.66$119.29M2.931.38 million shs1.37 million shsHLVXHilleVax$1.85-3.6%$1.85$1.34▼$15.60$92.76M0.74446,931 shs354,921 shsTCRXTScan Therapeutics$1.55-3.7%$1.45$1.02▼$9.08$87.72M0.98415,059 shs194,449 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%CCCCC4 Therapeutics+3.70%-2.89%+22.63%-17.24%-66.13%HLVXHilleVax-3.65%-7.04%-3.14%+5.71%-87.33%TCRXTScan Therapeutics-3.73%-13.89%+21.09%-10.92%-82.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTCApplied Genetic Technologies0.155 of 5 stars0.00.00.03.80.60.00.0CCCCC4 Therapeutics2.1948 of 5 stars3.32.00.00.02.71.70.6HLVXHilleVax3.2332 of 5 stars3.03.00.00.03.23.31.3TCRXTScan Therapeutics3.7306 of 5 stars3.55.00.00.03.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTCApplied Genetic Technologies 0.00N/AN/AN/ACCCCC4 Therapeutics 2.50Moderate Buy$12.00614.29% UpsideHLVXHilleVax 2.00Hold$3.0062.16% UpsideTCRXTScan Therapeutics 3.00Buy$7.80403.23% UpsideCurrent Analyst Ratings BreakdownLatest AGTC, CCCC, TCRX, and HLVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025TCRXTScan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $10.005/6/2025TCRXTScan TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$7.004/8/2025TCRXTScan TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/31/2025HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/14/2025TCRXTScan TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$10.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51CCCCC4 Therapeutics$39.78M3.00N/AN/A$4.07 per share0.41HLVXHilleVaxN/AN/AN/AN/A$5.48 per shareN/ATCRXTScan Therapeutics$4.42M19.84N/AN/A$3.15 per share0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/ACCCCC4 Therapeutics-$132.49M-$1.47N/AN/AN/A-313.35%-42.45%-27.55%7/30/2025 (Estimated)HLVXHilleVax-$123.57M-$2.15N/AN/AN/AN/A-67.27%-51.99%8/14/2025 (Estimated)TCRXTScan Therapeutics-$89.22M-$1.09N/AN/AN/A-1,188.88%-58.72%-36.02%8/11/2025 (Estimated)Latest AGTC, CCCC, TCRX, and HLVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TCRXTScan Therapeutics-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/A5/7/2025Q1 2025CCCCC4 Therapeutics-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million3/28/2025Q4 2024HLVXHilleVax-$0.33-$0.35-$0.02-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTCApplied Genetic Technologies0.391.401.40CCCCC4 TherapeuticsN/A6.316.31HLVXHilleVaxN/A14.2514.25TCRXTScan Therapeutics0.139.569.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTCApplied Genetic Technologies22.05%CCCCC4 Therapeutics78.81%HLVXHilleVax86.42%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipAGTCApplied Genetic Technologies4.10%CCCCC4 Therapeutics8.73%HLVXHilleVax24.90%TCRXTScan Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableCCCCC4 Therapeutics15071.01 million64.55 millionOptionableHLVXHilleVax2050.14 million14.39 millionNot OptionableTCRXTScan Therapeutics10056.59 million51.90 millionNot OptionableAGTC, CCCC, TCRX, and HLVX HeadlinesRecent News About These CompaniesTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Buy" from BrokeragesJune 14 at 3:44 AM | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street ZenJune 14 at 2:19 AM | americanbankingnews.comWall Street Zen Downgrades TScan Therapeutics (NASDAQ:TCRX) to SellJune 14 at 2:16 AM | marketbeat.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest UpdateJune 3, 2025 | marketbeat.comTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comLynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockMay 22, 2025 | insidertrades.comTScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comWhat Analysts Are Saying About TScan Therapeutics StockMay 10, 2025 | nasdaq.com3TCRX : What Analysts Are Saying About TScan Therapeutics StockMay 7, 2025 | benzinga.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comTScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comTScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual MeetingApril 30, 2025 | nasdaq.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual MeetingApril 28, 2025 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%April 17, 2025 | aaii.comNeedham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)April 9, 2025 | markets.businessinsider.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 17.27%April 8, 2025 | aaii.comTScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTScan Therapeutics appoints Camiolo as SVP, Market AccessMarch 27, 2025 | markets.businessinsider.comTScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market AccessMarch 27, 2025 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 10.92%March 18, 2025 | aaii.comTScan Therapeutics assumed with an Overweight at Morgan StanleyMarch 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGTC, CCCC, TCRX, and HLVX Company DescriptionsApplied Genetic Technologies NASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.C4 Therapeutics NASDAQ:CCCC$1.68 +0.06 (+3.70%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.66 -0.01 (-0.89%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.HilleVax NASDAQ:HLVX$1.85 -0.07 (-3.65%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.85 0.00 (0.00%) As of 06/13/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.TScan Therapeutics NASDAQ:TCRX$1.55 -0.06 (-3.73%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.53 -0.02 (-1.29%) As of 06/13/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
